In vitro anti-tumor effects of statins on head and neck squamous cell carcinoma: A systematic review

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Pavan, Ludmila Madeira Cardoso ^a   Rêgo, Daniela Fortunato ^a   Elias, Silvia Taveira ^a   De Luca Canto, Graziela ^b   Guerra, Eliete Neves Silva ^a  

^a UNIVERSITY OF BRASILIA   (Brazil)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE KINASE; AMLODIPINE BESYLATE; ATORVASTATIN; CASPASE 3; CETUXIMAB; CISPLATIN; CYCLIN D1; CYCLIN D2; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLUOROURACIL; GEFITINIB; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; GUANOSINE TRIPHOSPHATASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INITIATION FACTOR 4E BINDING PROTEIN 1; LIVER KINASE B1; MEVALONIC ACID; MEVINOLIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MONENSIN; PHOSPHOTRANSFERASE; PRAVASTATIN; PROTEIN KINASE B; PROTEIN RHOC; SALUBRINAL; SIMVASTATIN; STAT3 PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; CANCER RADIOTHERAPY; CARCINOMA CELL LINE; CELL CYCLE ARREST; CELL DEATH; CELL VIABILITY; CONCENTRATION RESPONSE; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG POTENTIATION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; IN VITRO STUDY; NONHUMAN; PROTEIN EXPRESSION; REVIEW; SYSTEMATIC REVIEW; CARCINOMA, SQUAMOUS CELL; HEAD AND NECK NEOPLASMS; HELA CELL LINE; MCF-7 CELL LINE; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; HEAD AND NECK NEOPLASMS; HELA CELLS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MCF-7 CELLS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84939172623     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0130476     Document Type: Review

References (37)

1. Endo A. A historical perspective on the discovery of statins. Proc Jpn Acad Ser B Phys Bio Sci 2010; 86:484-93. PMID: 20467214.
2. Endo A. The discovery special article and development of HMG-CoA reductase inhibitors. J Lip Res 1992; 33:1569-82.
3. Buchwald H. Cholesterol inhibition, cancer, and chemotherapy. Lancet 1992; 339(8802):1154-06. PMID: 1349377.
4. Corsini A, Maggi FM, Catapano AL. Pharmacology of competitive inhibitors of HMG-CoA reductase. Pharmacol Res 1995; 31:9-27. PMID: 7784310.
5. Chan KK, Oza AM, Siu LL. The statins as anticancer agents. Clin Cancer Res 2003; 9:10-19. PMID: 12538446.
6. Niknejad N, Gorn-Hondermann I, Ma L, Zahr S, Johnson-Obeseki S, Corsten M, et al. Lovastatininduced apoptosis is mediated by activating transcription factor 3 and enhanced in combination with salubrinal. Int J Cancer 2014; 134:268-79. doi:10.1002/ijc.28369 PMID: 23824972.
7. Islam M, Sharma S, Kumar B, Teknos TN. Atorvastatin inhibits RhoC function and limits head and neck cancer metastasis. Oral Oncol 2013; 49:778-86. doi:10.1016/j.oraloncology.2013.04.003 PMID: 23648017.
8. Ma L, Niknejad N, Gorn-Hondermann I, Dayekh K, Dimitroulakos J. Lovastatin induces multiple stress pathways including LKB1/AMPK activation that regulate its cytotoxic effects in squamous cell carcinoma cells. Plos One 2012; 7: E46055. doi:10.1371/journal.pone.0046055 PMID: 23029387.
9. Dimitroulakos J, Marhin WH, Tokunaga J, Irish J, Gullane P, Penn LZ, et al. Microarray and biochemical analysis of lovastatin-induced apoptosis of squamous cell carcinomas. Neoplasia 2002; 4:337-46. PMID: 12082550.
10. Knox JJ, Siu LL, Chen E, Dimitroulakos J, Kamel-Reid S, Moore MJ, et al. A Phase I trial of prolonged administration of lovastatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or of the cervix. Eur J Cancer 2005; 41:523-30. PMID: 15737556.
11. Mantha AJ, Hanson JE, Goss G, Lagarde AE, Lorimer IA, Dimitroulakos J. Targeting the mevalonate pathway inhibits the function of the epidermal growth factor receptor. Clin Cancer Res 2005; 11:2398- 07. PMID: 15788691.
12. Altman JK, Sassano A, Platanias LC. Targeting mTOR for the treatment of AML. New agents and new directions. Oncotarget 2011; 2:510-07. PMID: 21680954.
13. Warnakulasuriya S. Global epidemiology of oral and oropharyngeal cancer. Oral Oncol 2009; 45:309- 16. doi:10.1016/j.oraloncology.2008.06.002 PMID: 18804401.
14. Blais L, Desgagne A, LeLorier J. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: A nested case-control study. Arch Intern Med 2000; 160: 2363-68. PMID: 10927735.
15. Graaf M, Beiderbeck A, Egberts A, et al. The risk of cancer in users of statins. J Clin Oncol 2004; 22: 2388-94. PMID: 15197200.
16. Moher D, Liberati A, Tetzlaff J, Altman DG; The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Ann Intern Med 2009; 151:264-69. PMID: 19622511.
17. Sobin LH, Gospodarowicz MK, Wittekind C. UICC TNM classification of malignant tumours. 7th ed. New York: Wiley-Liss, 2009.
18. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction- GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 2011; 64:383-94. doi:10.1016/j.jclinepi.2010.04.026 PMID: 21195583.
19. Xiao Z, Li C, Shan J, Luo L, Feng L, Lu J, et al. Interventions to improve chronic cyclosporine. A nephrotoxicity through inhibiting renal cell apoptosis: A systematic review. Chinese Med J (Engl) 2013; 126:3767-74.
20. Dimitroulakos J, Ye LY, Benzaquen M, Moore MJ, Kamel-Reid S, Freedman MH, et al. Differential sensitivity of various pediatric cancers and squamous cell carcinomas to lovastatin-induced apoptosis: Therapeutic implications. Clin Cancer Res 2001; 7:158-67. PMID: 11205904.
21. Mantha AJ, McFee KE, Niknejad N, Goss G, Lorimer IA, Dimitroulakos J. Epidermal growth factor receptor-targeted therapy potentiates lovastatin-induced apoptosis in head and neck squamous cell carcinoma cells. J Cancer Res Clin Oncol 2003; 129:631-41. PMID: 12942316.
22. Niknejad N, Morley M, Dimitroulakos J. Activation of the integrated stress response regulates lovastatin- induced apoptosis. J Biol Chem 2007; 282:29748-56. PMID: 17699156.
23. Dayekh K, Johnson-Obaseki, Corsten M, Villeneuve P, Sekhon H, Weberpals J et al. Monensin inhibits epidermal growth factor receptor trafficking and activation: Synergistic cytotoxicity in combination with EGFR inhibitors. Mol Cancer Ther 2014; 13:2559-71. doi:10.1158/1535-7163.MCT-13-1086 PMID: 25189541.
24. Pioche-Durieu C, Keryer C, Souquöure S, Bosq J, Faigle W, Loew D, et al. In nasopharyngeal carcinoma cells, Epstein-Barr virus LMP1 interacts with galectin 9 in membrane raft elements resistant to simvastatin. J Virol 2005; 79:13326-37. PMID: 16227255.
25. Gabrýs D, Dörfler A, Yaromina A, Hessel F, Krause M, Oertel R, et al. Effects of lovastatin alone or combined with irradiation on tumor cells in vitro and in vivo. Strahlenther Onkol 2008; 184:48-53. doi:10.1007/s00066-008-1805-7 PMID: 18188523.
26. Llobet L, Baro M, Mesia R, Balart J. Simvastatin enhances the effects of radiotherapy and cetuximab on a cell line (FaDu) derived from a squamous cell carcinoma of head and neck. Transl Oncol 2014; 7:513-22. doi:10.1016/j.tranon.2014.02.008 PMID: 25171892.
27. Takeda I, Maruya S, Shirasaki T, Mizukami H, Takahata T, Myers JN, et al. Simvastatin inactivates beta1-integrin and extracellular signal-related kinase signaling and inhibits cell proliferation in head and neck squamous cell carcinoma cells. Cancer Sci 2007; 98:890-9. PMID: 17428261.
28. Wang W, Le W, Cho DY, Hwang PH, Upadhyay D. Novel effects of statins in enhancing efficacy of chemotherapy in vitro in nasopharyngeal carcinoma. Int Forum Allergy Rhinol 2011; 1:284-9. doi:10.1002/alr.20039 PMID: 22287433.
29. Kundu SK, Nestor M. Targeted therapy in head and neck cancer. Tumour Biol 2012; 33:707-21. doi:10.1007/s13277-012-0350-2 PMID: 22373581.
30. Warnakulasuriya S. Causes of oral cancer- An appraisal of controversies. Br Dent J 2009; 207:471-5. doi:10.1038/sj.bdj.2009.1009 PMID: 19946320.
31. Petti S. Lifestyle risk factors for oral cancer. Oral Oncol 2009; 45:340-50. doi:10.1016/j.oraloncology.2008.05.018 PMID: 18674956.
32. Thavaraj S, Stokes A, Guerra E, Bible J, Halligan E, Long A, et al. Evaluation of human papillomavirus testing for squamous cell carcinoma of the tonsil in clinical practice. J Clin Pathol 2011; 64:308-12. doi:10.1136/jcp.2010.088450 PMID: 21345874.
33. Psyrri A, Fountzilas G. Advances in the treatment of locally advanced non-nasopharyngeal squamous cell carcinoma of the head and neck region. Med Oncol 2006; 23:1-15. PMID: 16645225.
34. Belcher R, Hayes K, Fedewa S, Chen AY. Current treatment of head and neck squamous cell cancer. J Surg Oncol 2014; 110:551-74. doi:10.1002/jso.23724 PMID: 25053506.
35. Dale KM, Coleman CI, Henyan NN, Kluger J, White CM. Statins and cancer risk: A meta-analysis. JAMA 2006; 295:74-80. PMID: 16391219.
36. Lennernäs H, Fager G. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Clin Pharmacokinet 1997; 32:403-25. PMID: 9160173.
37. Gartel AL, Radhaskrishnan SK. Lost in trascription: P21 repression, mechanisms and consequences. Cancer Res 2005; 65:3980-5. PMID: 15899785.